The New England journal of medicine, 2022-02, Vol.386 (6), p.556-567
- Schmid, Peter
- Cortes, Javier
- Dent, Rebecca
- Pusztai, Lajos
- McArthur, Heather
- Kümmel, Sherko
- Bergh, Jonas
- Denkert, Carsten
- Park, Yeon Hee
- Hui, Rina
- Harbeck, Nadia
- Takahashi, Masato
- Untch, Michael
- Fasching, Peter A
- Cardoso, Fatima
- Andersen, Jay
- Patt, Debra
- Danso, Michael
- Ferreira, Marta
- Mouret-Reynier, Marie-Ange
- Im, Seock-Ah
- Ahn, Jin-Hee
- Gion, Maria
- Baron-Hay, Sally
- Boileau, Jean-François
- Ding, Yu
- Tryfonidis, Konstantinos
- Aktan, Gursel
- Karantza, Vassiliki
- O’Shaughnessy, Joyce
2022
Details
- Autor(en) / Beteiligte
- Schmid, Peter
- Cortes, Javier
- Dent, Rebecca
- Pusztai, Lajos
- McArthur, Heather
- Kümmel, Sherko
- Bergh, Jonas
- Denkert, Carsten
- Park, Yeon Hee
- Hui, Rina
- Harbeck, Nadia
- Takahashi, Masato
- Untch, Michael
- Fasching, Peter A
- Cardoso, Fatima
- Andersen, Jay
- Patt, Debra
- Danso, Michael
- Ferreira, Marta
- Mouret-Reynier, Marie-Ange
- Im, Seock-Ah
- Ahn, Jin-Hee
- Gion, Maria
- Baron-Hay, Sally
- Boileau, Jean-François
- Ding, Yu
- Tryfonidis, Konstantinos
- Aktan, Gursel
- Karantza, Vassiliki
- O’Shaughnessy, Joyce
- Titel
- Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
- Ist Teil von
- The New England journal of medicine, 2022-02, Vol.386 (6), p.556-567
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- An interim analysis of a randomized trial in triple-negative breast cancer comparing the addition of pembrolizumab to neoadjuvant chemotherapy with chemotherapy alone and adjuvant pembrolizumab with placebo after definitive surgery was reported after 39 months of follow-up. Event-free survival at 3 years was 84.5% in the pembrolizumab group and 76.8% in the group that did not receive pembrolizumab.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa2112651Titel-ID: cdi_swepub_primary_oai_prod_swepub_kib_ki_se_235139274
- Format
- –
- Schlagworte
- Adult, Aged, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Antineoplastic Agents, Immunological - adverse effects, Antineoplastic Agents, Immunological - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Breast Cancer, Cancer och onkologi, Cancer therapies, Carboplatin, Chemotherapy, Chemotherapy, Adjuvant, Committees, Cyclophosphamide, Doxorubicin, Epirubicin, Farmakologi och toxikologi, Female, Hematology, Humans, Immunotherapy, Intention to Treat Analysis, Invasiveness, Kaplan-Meier Estimate, Klinisk medicin, Life Sciences, Lymphatic system, Medicin och hälsovetenskap, Medicinska och farmaceutiska grundvetenskaper, Middle Aged, Monoclonal antibodies, Neoadjuvant Therapy, Oncology, Paclitaxel, Patients, Pembrolizumab, Placebos, Progression-Free Survival, Radiation therapy, Statistical analysis, Surgery, Survival, Targeted cancer therapy, Treatments in Oncology, Triple Negative Breast Neoplasms - drug therapy, Triple Negative Breast Neoplasms - surgery, Tumors